结肠腺癌（COAD）的临床结果在不同患者之间表现出异质性，凸显了对新型预后生物标志物的需求。驱动蛋白超家族成员已被证明在肿瘤中发挥着至关重要的作用，并且可以预测癌症的诊断和预后。然而，驱动蛋白家族成员 C2 (KIFC2) 在肿瘤中的作用，特别是其在 COAD 中的预后价值，仍然知之甚少。我们对癌症基因组图谱和 GEO 数据库的生物信息学分析显示，COAD 中 KIFC2 的表达显着较高，与癌症基因组图谱-COAD 和 GSE17536 队列中较差的预后相关。此外，COAD 中差异表达的基因在免疫相关通路中富集，KIFC2 表达较高的患者表现出较少的活化 CD4 T 细胞。这些发现表明 KIFC2 作为 COAD 的潜在预后生物标志物，值得在临床研究中进一步验证。版权所有 © 2023 作者。由 Wolters Kluwer Health, Inc. 出版

Clinical outcomes of colon adenocarcinoma (COAD) exhibit heterogeneity among different patients, highlighting the need for novel prognostic biomarkers. Kinesin superfamily members have been shown to play a crucial role in tumors and can predict cancer diagnosis and prognosis. However, the role of kinesin family member C2 (KIFC2) in tumors, particularly its prognostic value in COAD, remains poorly understood. Our bioinformatics analysis of the cancer genome atlas and GEO databases revealed significantly higher expression of KIFC2 in COAD, correlating with a worse prognosis in the cancer genome atlas-COAD and GSE17536 cohorts. Additionally, differentially expressed genes in COAD were enriched in immune-related pathways, and patients with higher KIFC2 expression showed fewer activated CD4 + T cells. These findings suggest KIFC2 as a potential prognostic biomarker for COAD, warranting further validation in clinical studies.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.